BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 26554657)

  • 1. Prognostic importance of CDK4/6-specific activity as a predictive marker for recurrence in patients with endometrial cancer, with or without adjuvant chemotherapy.
    Ikeda Y; Oda K; Ishihara H; Wada-Hiraike O; Miyasaka A; Kashiyama T; Inaba K; Fukuda T; Sone K; Matsumoto Y; Arimoto T; Maeda D; Ikemura M; Fukayama M; Kawana K; Yano T; Aoki D; Osuga Y; Fujii T
    Br J Cancer; 2015 Nov; 113(10):1477-83. PubMed ID: 26554657
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunohistochemical expression of cyclins, cyclin-dependent kinases, tumor-suppressor gene products, Ki-67, and sex steroid receptors in endometrial carcinoma: positive staining for cyclin A as a poor prognostic indicator.
    Shih HC; Shiozawa T; Kato K; Imai T; Miyamoto T; Uchikawa J; Nikaido T; Konishi I
    Hum Pathol; 2003 May; 34(5):471-8. PubMed ID: 12792921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loss of ASRGL1 expression is an independent biomarker for disease-specific survival in endometrioid endometrial carcinoma.
    Edqvist PH; Huvila J; Forsström B; Talve L; Carpén O; Salvesen HB; Krakstad C; Grénman S; Johannesson H; Ljungqvist O; Uhlén M; Pontén F; Auranen A
    Gynecol Oncol; 2015 Jun; 137(3):529-37. PubMed ID: 25858696
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The importance of adjuvant chemotherapy and pelvic radiotherapy in high-risk early stage endometrial carcinoma.
    Jutzi L; Hoskins P; Lim P; Aquino-Parsons C; Tinker A; Kwon JS
    Gynecol Oncol; 2013 Dec; 131(3):581-5. PubMed ID: 24055614
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The value of Ki-67 antigen expression in tissue microarray method in prediction prognosis of patients with endometrioid endometrial cancer].
    Gottwald L; Kubiak R; Sek P; Piekarski J; Szwalski J; Pasz-Walczak G; Spych M; Suzin J; Tylińskis W; Jeziorski A
    Ginekol Pol; 2013 Jun; 84(6):444-9. PubMed ID: 24032262
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progesterone receptor negativity is an independent risk factor for relapse in patients with early stage endometrioid endometrial adenocarcinoma.
    Huvila J; Talve L; Carpén O; Edqvist PH; Pontén F; Grénman S; Auranen A
    Gynecol Oncol; 2013 Sep; 130(3):463-9. PubMed ID: 23777659
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic Significance of POLE Exonuclease Domain Mutations in High-Grade Endometrioid Endometrial Cancer on Survival and Recurrence: A Subanalysis.
    Billingsley CC; Cohn DE; Mutch DG; Hade EM; Goodfellow PJ
    Int J Gynecol Cancer; 2016 Jun; 26(5):933-8. PubMed ID: 26937754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrative Protein-Based Prognostic Model for Early-Stage Endometrioid Endometrial Cancer.
    Yang JY; Werner HM; Li J; Westin SN; Lu Y; Halle MK; Trovik J; Salvesen HB; Mills GB; Liang H
    Clin Cancer Res; 2016 Jan; 22(2):513-23. PubMed ID: 26224872
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinicopathological significance of PSF3 expression in uterine endometrial carcinomas.
    Park JK; Otsuka N; Tomaru U; Suzuki H; Azuma M; Okamoto K; Yamashiro K; Kasahara M
    Hum Pathol; 2018 Oct; 80():104-112. PubMed ID: 29936059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peritoneal cytology: a risk factor of recurrence for non-endometrioid endometrial cancer.
    Han KH; Park NH; Kim HS; Chung HH; Kim JW; Song YS
    Gynecol Oncol; 2014 Aug; 134(2):293-6. PubMed ID: 24854062
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cleaved caspase-3 expression is a potential prognostic factor for endometrial cancer with positive peritoneal cytology.
    Ogane N; Yasuda M; Kato H; Kato T; Yano M; Kameda Y; Kamoshida S
    Cytopathology; 2018 Jun; 29(3):254-261. PubMed ID: 29626374
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant chemotherapy as treatment of high-risk stage I and II endometrial cancer.
    Aoki Y; Watanabe M; Amikura T; Obata H; Sekine M; Yahata T; Fujita K; Tanaka K
    Gynecol Oncol; 2004 Aug; 94(2):333-9. PubMed ID: 15297170
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular and immunohistochemical analysis of the prognostic value of cell-cycle regulators in urothelial neoplasms of the bladder.
    Yurakh AO; Ramos D; Calabuig-Fariñas S; López-Guerrero JA; Rubio J; Solsona E; Romanenko AM; Vozianov AF; Pellin A; Llombart-Bosch A
    Eur Urol; 2006 Sep; 50(3):506-15; discussion 515. PubMed ID: 16624482
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The cell cycle profiling-risk score based on CDK1 and 2 predicts early recurrence in node-negative, hormone receptor-positive breast cancer treated with endocrine therapy.
    Kim SJ; Masuda N; Tsukamoto F; Inaji H; Akiyama F; Sonoo H; Kurebayashi J; Yoshidome K; Tsujimoto M; Takei H; Masuda S; Nakamura S; Noguchi S
    Cancer Lett; 2014 Dec; 355(2):217-23. PubMed ID: 25218592
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical implications and prognostic value of single and combined biomarkers in endometrial carcinoma.
    Li M; Zhao L; Shen D; Li X; Wang J; Wei L
    Chin Med J (Engl); 2014; 127(8):1459-63. PubMed ID: 24762589
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CDK1 and CDK2 activity is a strong predictor of renal cell carcinoma recurrence.
    Hongo F; Takaha N; Oishi M; Ueda T; Nakamura T; Naitoh Y; Naya Y; Kamoi K; Okihara K; Matsushima T; Nakayama S; Ishihara H; Sakai T; Miki T
    Urol Oncol; 2014 Nov; 32(8):1240-6. PubMed ID: 25443276
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Durable response in a woman with recurrent low-grade endometrioid endometrial cancer and a germline BRCA2 mutation treated with a PARP inhibitor.
    Gockley AA; Kolin DL; Awtrey CS; Lindeman NI; Matulonis UA; Konstantinopoulos PA
    Gynecol Oncol; 2018 Aug; 150(2):219-226. PubMed ID: 29937315
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of serum CA-125 levels for preoperative counseling in endometrioid endometrial cancer: a multi-center study.
    Kim HS; Park CY; Lee JM; Lee JK; Cho CH; Kim SM; Kim JW
    Gynecol Oncol; 2010 Sep; 118(3):283-8. PubMed ID: 20541245
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of preoperative metabolic tumor volume measured by ¹⁸F-FDG PET/CT and MRI in patients with endometrial cancer.
    Chung HH; Lee I; Kim HS; Kim JW; Park NH; Song YS; Cheon GJ
    Gynecol Oncol; 2013 Sep; 130(3):446-51. PubMed ID: 23791826
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Placental leucine aminopeptidase (P-LAP) expression is associated with chemosensitivity in human endometrial carcinoma.
    Shibata K; Kikkawa F; Kondo C; Mizokami Y; Kajiyama H; Ino K; Nomura S; Mizutani S
    Gynecol Oncol; 2004 Nov; 95(2):307-13. PubMed ID: 15491750
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.